Show simple item record

dc.contributor.authorOlveda, David U
dc.contributor.authorInobaya, Marianette T
dc.contributor.authorMcManus, Donald P
dc.contributor.authorOlveda, Remigio M
dc.contributor.authorVinluan, Marilyn L
dc.contributor.authorNg, Shu-Kay
dc.contributor.authorHarn, Donald A
dc.contributor.authorLi, Yuesheng
dc.contributor.authorGuevarra, Jerric R
dc.contributor.authorLam, Alfred K
dc.contributor.authorRoss, Allen GP
dc.date.accessioned2017-09-28T12:30:38Z
dc.date.available2017-09-28T12:30:38Z
dc.date.issued2017
dc.identifier.issn1201-9712
dc.identifier.doi10.1016/j.ijid.2016.10.001
dc.identifier.urihttp://hdl.handle.net/10072/143186
dc.description.abstractObjective: This study assessed the impact of annual versus biennial praziquantel treatment regimens on the prevalence, intensity of infection, and liver fibrosis dynamics of Asiatic schistosomiasis (caused by Schistosoma japonicum) among individuals residing in 18 endemic barangays in Northern Samar, Philippines. Methods: Five hundred and sixty-five subjects who reported symptoms of gastrointestinal illness and/or were believed to have clinical morbidity based on physical examination were selected for cohort follow-up. Results: The mean prevalence of schistosomiasis was 34% and the mean intensity of infection was 123.1 eggs per gram. Moderate to severe hepatic fibrosis (grade II/III) was demonstrated in approximately 25% of the study population. As expected, a greater reduction in both the prevalence and intensity of infection was documented with two treatment rounds versus one. Overall, hepatic fibrosis (grades I–III) regressed in only 24.3% of those who received a single treatment and in only 19.3% of those who received two doses. The prevalence of grade II–III fibrosis at baseline (25.2%) remained unchanged 2 years after treatment. Conclusions: These findings suggest that in order to reverse moderate to severe liver fibrosis due to schistosomiasis and improve clinical outcomes, a higher clinical dosage of praziquantel (i.e., 60–80 mg/kg) may be required over an extended duration.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto5
dc.relation.ispartofjournalInternational Journal of Infectious Diseases
dc.subject.fieldofresearchMicrobiology
dc.subject.fieldofresearchMedical microbiology
dc.subject.fieldofresearchMedical microbiology not elsewhere classified
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchEpidemiology
dc.subject.fieldofresearchcode3107
dc.subject.fieldofresearchcode3207
dc.subject.fieldofresearchcode320799
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4206
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode4202
dc.titleBiennial versus annual treatment for schistosomiasis and its impact on liver morbidity
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/bync-nd/4.0/
dc.description.versionVersion of Record (VoR)
gro.facultyGriffith Health, School of Medical Science
gro.rights.copyright© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
gro.hasfulltextFull Text
gro.griffith.authorLam, Alfred K.
gro.griffith.authorNg, Shu Kay Angus
gro.griffith.authorRoss, Allen G.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record